GRISEOFULVIN, ULTRAMICROSIZE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for griseofulvin, ultramicrosize and what is the scope of patent protection?
Griseofulvin, ultramicrosize
is the generic ingredient in six branded drugs marketed by Chartwell Rx, Bausch, Mountain, Sandoz, and Sigmapharm Labs Llc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.Five suppliers are listed for this compound.
Summary for GRISEOFULVIN, ULTRAMICROSIZE
| US Patents: | 0 |
| Tradenames: | 6 |
| Applicants: | 5 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 96 |
| Patent Applications: | 6,969 |
| DailyMed Link: | GRISEOFULVIN, ULTRAMICROSIZE at DailyMed |
Pharmacology for GRISEOFULVIN, ULTRAMICROSIZE
| Drug Class | Tubulin Inhibiting Agent |
| Physiological Effect | Decreased Mitosis Microtubule Inhibition |
Anatomical Therapeutic Chemical (ATC) Classes for GRISEOFULVIN, ULTRAMICROSIZE
US Patents and Regulatory Information for GRISEOFULVIN, ULTRAMICROSIZE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sigmapharm Labs Llc | GRISEOFULVIN,ULTRAMICROSIZE | griseofulvin, ultramicrosize | TABLET;ORAL | 202545-001 | Oct 22, 2012 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | FULVICIN P/G 330 | griseofulvin, ultramicrosize | TABLET;ORAL | 061996-004 | Apr 6, 1982 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sandoz | GRISEOFULVIN, ULTRAMICROSIZE | griseofulvin, ultramicrosize | TABLET;ORAL | 202805-001 | Dec 26, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch | GRIS-PEG | griseofulvin, ultramicrosize | TABLET;ORAL | 050475-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
